Immunome Q1 EPS $(0.52) Beats $(0.69) Estimate
Portfolio Pulse from Benzinga Newsdesk
Immunome reported Q1 earnings with losses of $(0.52) per share, surpassing the analyst consensus estimate of $(0.69) by 24.64%. However, this represents a 48.57% increase in losses compared to the same period last year, where losses were $(0.35) per share.
May 13, 2024 | 12:24 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Immunome's Q1 earnings outperformed analyst expectations, showing a significant beat but also a notable increase in losses year-over-year.
While beating EPS estimates typically has a positive impact on stock prices, the significant increase in year-over-year losses could temper investor enthusiasm. The mixed results present a neutral outlook in the short term as investors weigh the beat against the increased losses.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100